Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

DiaMedica cleared to commence second phase II DM-71 trial in type 2 diabetes

Jan. 19, 2009

WHIMS-MRI Study evaluates effects of hormone therapy on brain volume, lesions

Jan. 19, 2009

Acceleron selects ACE-536 as new development candidate for anemia

Jan. 19, 2009

Modigene reports results from pilot toxicity study of hGH-CTP in primates

Jan. 19, 2009

Roche divulges new GPCR-targeting antibodies for diabetes and neurological disorders

Jan. 16, 2009

Amicus Therapeutics presents progress of three lead clinical programs

Jan. 16, 2009

FDA advisory committee to discuss Dyax's BLA for DX-88 in HAE

Jan. 16, 2009

Repros reports results from phase II trial of Proellex in endometriosis

Jan. 15, 2009

Qnexa treatment improves glucose control in obese nondiabetic subjects

Jan. 15, 2009

Santen describes novel glucocorticoid receptor ligands for metabolic disorders, among others

Jan. 15, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...